INSMED INC's ticker is INSM and the CUSIP is 457669307. A total of 213 filers reported holding INSMED INC in Q4 2021. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,555,109 | +21.1% | 297,797 | -2.8% | 0.17% | +36.2% |
| Q2 2023 | $6,239,260 | +16.0% | 306,447 | -2.9% | 0.13% | +16.5% |
| Q1 2023 | $5,380,042 | -15.6% | 315,545 | -1.1% | 0.11% | -16.2% |
| Q4 2022 | $6,376,337 | -8.8% | 319,136 | -1.6% | 0.13% | -10.3% |
| Q3 2022 | $6,988,000 | +6.2% | 324,440 | -2.8% | 0.14% | +11.5% |
| Q2 2022 | $6,579,000 | -13.6% | 333,630 | +2.9% | 0.13% | +6.6% |
| Q1 2022 | $7,617,000 | -13.8% | 324,129 | -0.1% | 0.12% | -4.7% |
| Q4 2021 | $8,841,000 | -3.3% | 324,560 | -2.2% | 0.13% | -5.9% |
| Q3 2021 | $9,140,000 | -4.5% | 331,865 | -1.4% | 0.14% | -4.2% |
| Q2 2021 | $9,575,000 | -13.5% | 336,425 | +3.6% | 0.14% | -14.5% |
| Q1 2021 | $11,063,000 | +13.7% | 324,820 | +11.1% | 0.17% | -7.3% |
| Q4 2020 | $9,729,000 | +6.5% | 292,255 | +2.8% | 0.18% | -11.8% |
| Q3 2020 | $9,136,000 | +41.1% | 284,255 | +20.9% | 0.20% | +31.0% |
| Q2 2020 | $6,474,000 | +208.4% | 235,094 | +79.6% | 0.16% | +150.0% |
| Q1 2020 | $2,099,000 | – | 130,925 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,533,883 | $44,590,000 | 16.02% |
| Foresite Capital Management II, LLC | 919,436 | $26,728,000 | 12.07% |
| NEXTHERA CAPITAL LP | 284,263 | $8,264,000 | 10.03% |
| Palo Alto Investors LP | 7,653,617 | $222,491,000 | 9.28% |
| Asymmetry Capital Management, L.P. | 154,887 | $4,503,000 | 7.52% |
| ACUTA CAPITAL PARTNERS, LLC | 370,000 | $10,756,000 | 5.11% |
| Vivo Capital, LLC | 1,170,290 | $34,020,000 | 3.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 110,000 | $3,198,000 | 1.18% |
| Islet Management, LP | 350,000 | $10,175,000 | 1.18% |
| EMERALD ADVISERS, LLC | 921,527 | $26,789,000 | 1.09% |